![](https://news.europawire.eu/wp-content/uploads/2013/10/AstraZeneca-144x150.jpg)
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission … Read the full press release